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A1 adenosine receptors (A1Rs) and adenosine deami-
nase (ADA; EC 3.5.4.4) interact on the cell surface of
DDT1MF-2 smooth muscle cells. The interaction facili-
tates ligand binding and signaling via A1R, but it is not
known whether it has a role in homologous desensitiza-
tion of A1Rs. Here we show that chronic exposure of
DDT1MF-2 cells to the A1R agonist, N
6-(R)-(phenyliso-
propyl)adenosine (R-PIA), caused a rapid aggregation
or clustering of A1 receptor molecules on the cell mem-
brane, which was enhanced by pretreatment with ADA.
Colocalization between A1R and ADA occurred in the
R-PIA-induced clusters. Interestingly, colocalization be-
tween A1R and ADA also occurred in intracellular vesi-
cles after internalization of both protein molecules in
response to R-PIA. Agonist-induced aggregation of A1Rs
was mediated by phosphorylation of A1Rs, which was
enhanced and accelerated in the presence of ADA. Li-
gand-induced second-messenger desensitization of A1Rs
was also accelerated in the presence of exogenous ADA,
and it correlated well with receptor phosphorylation.
However, although phosphorylation of A1R returned to
its basal state within minutes, desensitization continued
for hours. The loss of cell-surface binding sites (seques-
tration) induced by the agonist was time-dependent
(t1⁄25 10 6 1 h) and was accelerated by ADA. All of these
results strongly suggest that ADA plays a key role in the
regulation of A1Rs by accelerating ligand-induced de-
sensitization and internalization and provide evidence
that the two cell surface proteins internalize via the
same endocytic pathway.
Adenosine is an autacoid that exerts its physiological ac-
tions through specific cell surface receptors. Four adenosine
receptors (A1, A2A, A2B, and A3), belonging to the family of G
protein-coupled receptors, have been cloned and pharmaco-
logically characterized (1). Acting through different adeno-
sine receptors, adenosine is a neuromodulator in both the
central and peripheral nervous systems (2, 3). Via A1 aden-
osine receptors (A1Rs),
1 adenosine reduces heart rate (4),
glomerular filtration rate, and renin release in the kidney (5);
it induces bronchoconstriction (6, 7) and inhibits lipolysis.
A1Rs can be coupled to different pertussis toxin-sensitive G
proteins (8–10), which mediate inhibition of adenylate cy-
clase (11) and regulate Ca21 and K1 channels and inositol
phosphate metabolism (1). A1R displays two different affini-
ties for agonist, which have classically been attributed to a
different coupling to heterotrimeric G proteins (12). Accord-
ing to this two-independent site model, coupled receptor-G
protein complexes display high affinity for agonists (Kd 5
0.1–0.2 nM), and uncoupled receptors display low affinity
(1–2 nM) (12, 13). The recently reported cluster-arranged
cooperative model predicts that the high and low affinity
sites are a consequence of the negative cooperativity of ago-
nist binding and do not seem to be related to the content of
free and G protein-coupled receptors (14). According to the
cluster-arranged cooperative model, the agonist-induced con-
version of the high to the low affinity state may partially
explain the ligand-induced desensitization of A1R (14, 15).
Receptors belonging to the G protein-coupled receptor family
are desensitized and down-regulated in response to agonist
stimulation. b2-Adrenergic receptors (b2-ARs) constitute the
best characterized system within the G protein-coupled recep-
tor family. Agonist-induced b2-AR desensitization is caused by
a conformational change of the agonist-occupied receptor that
facilitates receptor phosphorylation by second messenger-acti-
vated kinases or G protein-coupled receptor kinases (16, 17).
Following b2-AR phosphorylation, b-arrestin binds to the phos-
phorylated receptor and uncouples the receptor from the het-
erotrimeric G proteins (18, 19). b-Arrestin not only desensitizes
the receptor but also functions as a clathrin adaptor, mediating
receptor sequestration, i.e. receptor internalization toward in-
tracellular compartments (20, 21). Although sequestration is
not required for phosphorylation and desensitization, it ap-
pears to be necessary for dephosphorylation and resensitiza-
tion of b2-ARs (22, 23).
Like other G protein-coupled receptor members, A1R ex-
pression is regulated in response to agonist or antagonist
stimulation. Desensitization of A1R has been described in
intact animals and in cell cultures. Prolonged administration
of A1R agonists to animals leads to functional desensitization
of A1R in guinea pig heart (24), rat adipocytes (25), rat atrial
muscle (26), and rat brain (27, 28). The reduced functional
response is due to a net loss of A1Rs or down-regulation, a
decrease in the proportion of A1R displaying the high affinity
state for agonists and a decrease in the content of Gi proteins.
Growth of rat adipocytes or smooth muscle DDT1MF-2 cells
in the presence of N6-(R)-(phenylisopropyl)adenosine (R-PIA)
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leads to the desensitization and down-regulation of A1R (29)
along with Gi a-subunits (30, 31). We have recently shown
that treatment of DDT1MF-2 cells with the agonist R-PIA
induces a rapid phosphorylation and clustering of A1Rs. The
loss of binding sites on the cell membrane due to internaliza-
tion of A1R is a slower event occurring within hours. Since
activators of protein kinase A or C mimicked the effect of the
ligand, Ser/Thr phosphorylation seems to be related to short
term clustering and desensitization as well as to long term
internalization of A1R (32).
A new perspective on the coupling of A1R to G proteins has
recently been provided. Ecto-adenosine deaminase (ecto-ADA;
EC 3.5.4.4), which is capable of degrading adenosine to inosine
on the cell surface (for a review, see Ref. 33), was shown to
modulate ligand binding and signaling through A1Rs on
DDT1MF-2 cells (34). Irrespective of its catalytic activity, ADA
seems to be necessary for a high affinity binding of agonists to
A1R (35).
Here the effect of ADA on the ligand-mediated regulation of
A1R in DDT1MF-2 cells has been studied. ADA affected both
desensitization and internalization of A1Rs. Moreover, by
means of immunocytochemistry, confocal microscopy, and flow
cytometry using antibodies against A1R and ADA, we found
that A1R and ADA colocalize and that, after receptor activa-
tion, they cluster on the cell surface and internalize via the
same pathway. All of these results provide evidence for con-
certed modulation of ADA and A1R in response to receptor
agonists.
EXPERIMENTAL PROCEDURES
Materials—[Adenine-2,8-3H,ethyl-2-3H]phenylisopropyladenosine
([3H]R-PIA) (36 Ci/mmol) was obtained from Amersham Pharmacia
Biotech (Nuclear Iberica, Madrid, Spain). [32P]orthophosphate (32Pi)
was from NEN Life Science Products. 1,3-Dipropyl-8-cyclopentylxan-
thine was from Research Biochemicals (Natick, MA). R-PIA, pepstatin,
leupeptin, chymostatin, antipain, phenylmethylsulfonyl fluoride, Fura-
2/AM, fluorescein isothiocyanate, rhodamine isothiocyanate, and calf
adenosine deaminase (ADA) were purchased from Sigma. ADA was
desalted with a Sephadex G-25 column (Amersham Pharmacia Biotech)
prior to all assays. A unit of enzyme activity corresponds to 130 nmol of
ADA protein. Electrophoresis reagents were obtained from Boehringer
Manheim. Sephadex G-25 and protein A-Sepharose CL4B were from
Pharmacia LKB Biotechnology (Uppsala, Sweden). All other products
were obtained from Merck.
Antibodies and Fluorescent Probes—Antisera against purified calf
ADA and against peptides of A1 adenosine receptor (PC10 and PC20)
were generated by immunization of female New Zealand White rabbits
by the Biokit Company (Barcelona, Spain). Antibodies against A1Rs
(PC11 and PC21) were purified from serum by affinity chromatography
(peptide coupled to thiol-Sepharose 4B (Amersham Pharmacia Bio-
tech)). Anti-ADA antibody was purified using ADA coupled to cyanogen
bromide-activated Sepharose (Amersham Pharmacia Biotech). The
specificity of antibodies for their respective antigens and extensive
characterization of anti-ADA and anti-A1R antibodies (PC11 and PC21)
have been previously reported (36, 37). PC11 and PC21 antibodies do
not recognize ADA from DDT1MF-2 cell extracts by immunoblotting,
immunoprecipitation, or immunocytochemistry (34). PC21 and PC11
A1R antibodies were shown to be specific for cells expressing A1Rs (32).
Fluorescence probes were obtained by reacting (for 2 h at 20 °C) 0.1
mg of fluorescein or rhodamine isothiocyanate with 1 mg of purified
protein in coupling buffer (50 mM H3BO3, 200 mM NaCl, pH 9.2).
Unbound fluorochrome was removed by rapid filtration through a Seph-
adex G-25 column (Amersham Pharmacia Biotech), and fractions were
tested for protein content. Aliquots were stored at 280 °C.
Cell Cultures and Protein Determination—DDT1MF-2 smooth mus-
cle cells derived from a steroid-induced leiomyosarcoma of Syrian ham-
ster vas deferens were obtained from the American Type Culture Col-
lection. Cells were cultured (at 37 °C, 5% CO2) in Dulbecco’s modified
Eagle’s medium (DMEM) (Whittaker, Walkersville, NY), 1% nonessen-
tial amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 5% (v/v)
horse serum, and 5% (v/v) fetal calf serum (Life Technologies, Inc.).
Desensitization and internalization assays were performed with cells
growing in the absence or in the presence of 65 nM ADA and/or 50 nM
R-PIA. At the indicated incubation times, cells were harvested and
washed exhaustively in cold phosphate-buffered saline (PBS) before
binding, immunocytochemistry, and intracellular calcium mobilization
assays.
Protein content was measured by the BCA method (Pierce), as de-
scribed by Sorensen and Brodbeck (38).
Radioligand Binding Assays—For binding assays, untreated or
treated DDT1MF-2 cells (1 mg/ml) were resuspended in serum-free
DMEM buffered with 20 mM HEPES, pH 7.4, and preincubated with 65
nM ADA for 30 min at 4 °C. Radioligand binding was performed in the
presence of 5 nM of [3H]R-PIA for 4 h at 4 °C. Nonspecific binding was
performed in the presence of a 400-fold excess of R-PIA. Nonspecific
binding with a 500-fold excess of the selective A1R antagonist 1,3-
dipropyl-8-cyclopentylxanthine resulted in similar displacement of
[3H]R-PIA binding. When equilibrium had been reached, incubates
were filtered through glass fiber filters (GF/C filters, Whatman, Kent,
United Kingdom) in a Brandel cell harvester (Biomedical Research and
Development Laboratories, Gaithersburg, MD). Filters were washed in
5 ml of ice-cold PBS and transferred to vials containing 10 ml of
scintillation solution EcoscintH (National Diagnostics, Atlanta, GA).
After overnight shaking, vials were counted using a Packard 1600
TRI-CARB scintillation counter with 50% efficiency. All points repre-
sent the mean of 3–5 independent experiments performed in triplicate.
Phosphorylation Assays—A1R phosphorylation was induced by 65 nM
ADA and/or 50 nM R-PIA treatment after the cellular ATP pool had
been labeled with [32P]orthophosphate. Briefly, DDT1MF-2 cells
washed twice and resuspended in phosphate-free DMEM (buffered with
20 mM HEPES, pH 7.4) were incubated (106 cells/ml, 37 °C, 2 h) with 0.1
mCi/ml [32P]orthophosphate. Loaded cells were resuspended (1 3 106
cells/ml) in serum-free DMEM and incubated with the indicated re-
agents at 37 °C. After the corresponding incubation times, cells were
centrifuged (10 s, 14,000 rpm) in a microcentrifuge and washed twice in
1 ml of ice-cold PBS before disruption and solubilization (1 h at 4 °C) in
0.5 ml of lysis buffer (20 mM HEPES, pH 7.4; 1% (v/v) Nonidet P-40; 100
mM NaCl; 1 mM Na3 VO4; 50 mM NaF; 1 mM phenylmethylsulfonyl
fluoride; 10 mg/ml leupeptin, pepstatin, chymostatin, and antipain). The
solubilized preparation (0.2 mg/ml) was immediately processed for im-
munoprecipitation with the anti-A1R antibody (PC11, 50 mg/ml) and
protein A-Sepharose beads. Immunoprecipitated material was washed
four times in lysis buffer (1 3 1%, 2 3 0.1%, and 1 3 0% Nonidet P-40)
before resuspension in 50 ml of SDS sample buffer. SDS-polyacrylamide
gel electrophoresis and autoradiography were performed as described
elsewhere (37). Phosphorylated bands were quantified with a comput-
ing densitometer (Molecular Dynamics, Inc.).
Immunostaining and Immunofluorescence Assays—For immunoflu-
orescence staining, treated and untreated cells were washed in PBS and
fixed in 4% paraformaldehyde in PBS, pH 7.4, for 15 min at room
temperature. After two washes in PBS containing 20 mM glycine (buffer
A) and in buffer A containing 1% bovine serum albumin (buffer B), cells
were incubated with the rhodamine-conjugated anti-A1R antibody
(PC21-TRITC, 75 mg/ml) and the fluorescein-conjugated anti-ADA an-
tibody (anti-ADA-FITC, 75 mg/ml) or, alternatively, with the fluoresce-
in-conjugated anti-A1R antibody (PC21-FITC, 75 mg/ml) for 1 h at 37 °C.
Three washes in buffer B were performed before mounting the samples
in immunofluorescence medium (ICN Biomedical Inc., Costa Mesa, CA).
Internalization was analyzed by immunocytochemistry and confocal
microscopy. To follow dynamic internalization, unfixed cells growing on
glass coverslips were incubated (37 °C, 20 min) with 65 nM bovine
serum albumin-FITC, with PC21-FITC (10 mg/ml), and with 65 nM
ADA-FITC and/or PC21-TRITC (10 mg/ml) and then treated with 50 nM
R-PIA at 37 °C for 24–72 h. Cells were washed twice in PBS, fixed in 4%
paraformaldehyde in PBS for 15 min, and again washed twice in PBS 20
mM glycine. Glass coverslips were mounted as described above. Cells
were examined with a LEICA TCS confocal scanning laser microscope
attached to an inverted Leitz DMIRBE microscope (Leica Lasertechnik
GmbH, Heidelberg). Images shown are representative of at least three
experiments.
Internalization measurements for A1Rs and cell surface ADA (ecto-
ADA) were performed by immunostaining and flow cytometry analysis.
Cells were grown in complete medium in the absence or presence of 50
nM R-PIA for 0–48 h. In some experiments, ADA (65 nM) was prebound
by incubation for 2 h at 4 °C; unbound enzyme was eliminated by
washing twice in PBS. Cells were fixed using 4% paraformaldehyde in
PBS for 15 min at room temperature. Cells were washed in buffer A and
buffer B for 20 min before staining with anti-ADA-FITC (75 mg/ml) or
PC21-FITC (75 mg/ml). Three washes in buffer B were performed before
analyzing the mean fluorescence intensity from 5000–10,000 cells on an
EPICS Profile flow cytometer (Coulter, Hieleah, FL). Similar assays
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were performed for cells incubated (30 min to 48 h at 37 °C) with 65 nM
fluorescein-conjugated ADA (ADA-FITC) in the absence or presence of
50 nM R-PIA. In order to remove as much of the cell surface-bound ADA
as possible, cells were washed once in PBS and once in PBS/HCl, pH 2,
for 15 min according to the method of Yang et al. (39). Cells were fixed
and processed for flow cytometry as described above. For establishing
comparisons in internalization studies, the mean of fluorescence inten-
sity taken as reference was that found in cells incubated with 65 nM
ADA-FITC for 15 min at 37 °C. This fluorescence intensity was similar
to that found in cells incubated with 65 nM ADA-FITC at 4 °C for 2 h,
which was considered as the background signal. Higher intensities
would reflect internalization of ADA-FITC.
Measurement of Intracellular Free Calcium—Cells were washed and
resuspended (5 3 106 cells/ml) in Hanks’ balanced salt solution (HBSS
containing 1.2 mM CaCl2 and 20 mM HEPES, pH 7.4) and loaded with
5 mM Fura-2/AM for 30 min at 25 °C. Cells were washed twice and
resuspended in HBSS (1 3 106 cells/ml) for 20 min at room tempera-
ture. Cells were placed in a cuvette (106 cells/2 ml of HBSS, 25 nM ADA),
and calcium peak induction was achieved by treatment with 50 nM
R-PIA at 30 °C. For short term desensitization assays (1–15 min), cells
were loaded and washed before resuspension in prewarmed (37 °C)
serum-free DMEM (1 3 106 cells/ml) and incubated with the indicated
reagents. Cells were washed three times in HBSS buffer to remove
reagents before resuspension in the same buffer and R-PIA induction of
calcium mobilization as indicated above. After these three washes
[Ca21] base-line levels were similar irrespective of the type of pretreat-
ment. Therefore, differences in calcium mobilization were not a conse-
quence of different calcium base-line levels in response to pretreat-
ments. For long term desensitization (12, 24, and 48 h), incubations
were performed before loading with Fura-2/AM. Calcium concentration
was determined in a dual wavelength Shimadzu RF-5000 spectroflu-
orophotometer by using the ratio of excitation wavelengths 334/366 nm
with emission cut-off at 500 nm. Free calcium concentration was calcu-
lated as described previously (40).
Statistical Analysis—Time course curves were fitted to a single-
phase exponential decay equation, in the case of [3H]R-PIA binding.
Statistical comparisons were made using the two-tailed Student’s t test.
Differences were considered significant when p was ,0.05.
RESULTS
Effect of ADA on Cell Surface Distribution of A1Rs in the
Absence and in the Presence of Agonist—A1 adenosine receptor
(A1R) distribution on the surface of DDT1MF-2 cells was exam-
ined by immunocytochemistry and confocal analysis. Un-
treated and R-PIA-treated cells were fixed, incubated with
fluorescein-conjugated rabbit anti-A1R antibody (PC21-FITC),
and analyzed by confocal microscopy. The PC21 antibody is
directed against the second extracellular loop of A1R and its
specificity for cell surface-expressed A1R has been previously
demonstrated (32). Receptor distribution in untreated cells re-
vealed homogenous bright staining on the surface of
DDT1MF-2 cells (Fig. 1A). No major differences in receptor
distribution were observed in the presence of exogenous ADA
(65 nM) for 15 min (Fig. 1B). A 5-min exposure of cells to the
A1R agonist R-PIA (50 nM) induced the appearance of bright
accumulations of antigen on the plasma membrane, suggesting
aggregation or clustering of receptor molecules (Fig. 1C). Clus-
tering of A1Rs was more evident after 15 min of R-PIA expo-
sure, when brighter clusters were found (Fig. 1, compare C and
E). Incubation of DDT1MF-2 cells with ADA and R-PIA
changed the pattern of cell surface A1R distribution dramati-
cally. In the presence of ADA, clusters of A1R were already
evident at 2 min, and the label was found as intense bright
punctate accumulations at 5 or 15 min of R-PIA treatment (Fig.
1, D and F). This clearly shows the involvement of ecto-ADA in
the regulation of the R-PIA-induced aggregation of cell surface
A1R molecules. All images shown in Fig. 1 represent recon-
structions of multiple sections at different levels. When middle
sections were analyzed, only the cell surface staining was ob-
served, thus ruling out intracellular staining (data not shown;
see Ref. 32).
To analyze the codistribution of A1R and ADA on the plasma
membrane of DDT1MF-2 cells, ADA-treated cells were incu-
bated with or without 50 nM R-PIA for 15 min. Cells were fixed,
washed, and stained by double immunofluorescence using the
fluorescein-conjugated anti-ADA antibody (anti-ADA-FITC)
and the rhodamine-conjugated anti-A1R antibody (PC21-
TRITC). Homogenous distribution of ADA and A1R on the cell
surface was observed in untreated cells (Fig. 2, top). Superim-
position of images by confocal analysis showed extensive colo-
calization (yellow) of both proteins on the plasma membrane.
When cells were treated (15 min) with R-PIA, a redistribution
of ADA and A1Rs, which is consistent with clustering, was
observed. R-PIA induced aggregation of both proteins in clus-
ters seen as punctate accumulations of fluorescence and where
colocalization between A1R and ecto-ADA was very high (Fig. 2,
bottom).
ADA Affects Ligand-induced Phosphorylation of A1Rs—In a
previous study, we have shown that ligand-induced phospho-
rylation of A1R correlates with the clustering of receptors on
the DDT1MF-2 cell surface (32). To determine whether the
potentiation of the clustering by ADA could involve changes in
receptor phosphorylation, we immunoprecipitated the receptor
from cells metabolically labeled with [32P]orthophosphate. Ex-
ogenous ADA by itself had only a slight effect on A1R phospho-
rylation. R-PIA (50 nM) induced, in the absence of ADA, a
steady increase of A1R phosphorylation from basal levels to a
2.1-fold increase at 15 min. Interestingly, in the presence of
exogenous ADA (65 nM), R-PIA induced a rapid increase in A1R
phosphorylation with a maximum rise (3-fold increase) after 1
min; thereafter (5 and 15 min), the level of phosphorylation
declined (Fig. 3). In the presence of ADA, receptor phosphoryl-
FIG. 1. Cell surface A1R redistribution in response to ADA
and/or R-PIA. DDT1MF-2 cells were untreated (A) or treated with 65
nM ADA (B), 50 nM R-PIA (C and E), or 65 nM ADA plus 50 nM R-PIA (D
and F) for 5 (C and D) or 15 min (A, B, E, and F) at 37 °C. Cells were
fixed, processed for immunofluorescence staining with the use of a
fluorescein-conjugated anti-A1R antibody (PC21-FITC, 75 mg/ml), and
observed by confocal microscopy. The images shown correspond to re-
constructions of several horizontal sections of representative cells.
Scale bar, 10 mm.
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ation diminished to basal level after 15–30 min, whereas for
cells treated with R-PIA in the absence of the enzyme the
return to basal levels of phosphorylation was slower.
Agonist-induced Desensitization of A1Rs in the Presence of
ADA—Activation of A1Rs with adenosine or analogs leads to
both Ins(1,4,5)P3 formation and intracellular calcium mobiliza-
tion in DDT1MF-2 cells (41, 42). To correlate changes in ago-
nist-induced A1R phosphorylation with possible changes in sec-
ond messenger production, we analyzed the effect of ADA
and/or R-PIA on agonist-induced mobilization of intracellular
calcium. Cells were exposed to vehicle (control) or to 65 nM ADA
and/or 50 nM R-PIA. After extensive washes, calcium mobiliza-
tion was induced by 50 nM R-PIA. R-PIA caused a transient
Ca21 peak in naive (vehicle-treated) cells (Fig. 4A). Desensiti-
zation of the [Ca21] response in R-PIA- or R-PIA/ADA-treated
cells occurred rapidly (in minutes) and was sustained for at
least 48 h (Fig. 4B). R-PIA pretreatment reduced the maximum
intracellular calcium concentration by 2, 30, and 44% at 1, 5,
and 15 min, respectively. This effect was, however, potentiated
in the presence of ADA, since the maximum desensitization
(60%) was achieved at 5 min and maintained for up to 48 h (Fig.
4, A and B). No significant differences in maximum effect were
observed when R-PIA pretreatment was done in the presence
or in the absence of ADA (Fig. 4B). It should be noted that ADA
pretreatment in the absence of R-PIA led to a significant and
sustained desensitization (25–45% reduction of the response).
Loss of A1Rs from the Cell Surface—Characterization of A1Rs
by radioligand binding using the agonist [3H]R-PIA indicated
the presence of two affinity states of the receptors (Khigh 5
0.8–2 nM and Klow 5 10–100 nM) in cell membrane prepara-
tions, whereas only the low affinity state was detected in intact
cells (43). Ligand binding assays were performed in intact cells
preincubated with vehicle (control) or with 50 nM R-PIA and/or
65 nM ADA. Cells were extensively washed and assayed for
[3H]R-PIA binding at 4 °C. The results indicated a time-de-
pendent loss of binding sites on the cell membrane of treated
cells (Fig. 5). The loss of binding sites after incubation of cells
with ADA in the absence of R-PIA was small. In contrast,
preincubation of cells with 50 nM R-PIA with or without ADA
resulted in a time-dependent reduction of [3H]R-PIA binding
sites. The presence of ADA accelerated the reduction of binding
sites, from t1⁄2 5 10 6 1 h to t1⁄2 5 2.9 6 0.5 h. The maximum loss
of cell surface binding sites (around 41%) induced by agonist
was not modified by the presence of ADA (Fig. 5).
Disappearance of A1Rs from the cell surface of DDT1MF-2
cells in response to agonist has been described elsewhere (32).
Interestingly, the effect of ADA was evident even when the
protein was prebound to the cell surface and the unbound
enzyme was washed away (Fig. 6). On the other hand, the
disappearance of A1Rs from the cell surface was reversible.
Thus, when chronically stimulated cells were further cultured
for 24 h in the absence of R-PIA, the level of cell surface
expression was recovered. These results indicate that, in the
presence of ADA, R-PIA induces the sequestration of A1R in
intracellular compartments (see below).
Internalization of A1Rs Together with ADA—In order to de-
termine whether agonist-induced disappearance of binding
sites affects the expression of cell surface ADA (ecto-ADA),
fluorocytometry analysis was performed using nonpermeabi-
FIG. 3. Agonist-induced phosphorylation of A1R in the absence
or presence of ADA. DDT1MF-2 cells were metabolically labeled with
32Pi and stimulated by means of vehicle (control), 65 nM ADA, and/or 50
nM R-PIA for 1 (white bars), 5 (gray bars), or 15 min (black bars) at
37 °C. A1R were immunoprecipitated and resolved by SDS-polyacryl-
amide gel electrophoresis. Gels were autoradiographed as described
under “Experimental Procedures,” and bands of phosphorylated A1R
were quantified with a computing densitometer (Molecular Dinamics).
Data are expressed as percentages of the basal level found in control
cells. Data are mean 6 S.E. of four separate experiments performed in
duplicate. *, p , 0.05; **, p , 0.005 with respect to the corresponding
control at 1, 5, or 15 min. The electrophoretic band (36 kDa) correspond-
ing to the A1R in a representative experiment is shown at the bottom.
FIG. 2. Colocalization between A1R
and ADA on the cell surface. Cells
were treated with 65 nM ADA in the ab-
sence (top) or presence (bottom) of 50 nM
R-PIA for 15 min at 37 °C. After treat-
ment, cells were washed, fixed, and proc-
essed for immunostaining as described
under “Experimental Procedures.” Stain-
ing was performed with the fluorescein-
conjugated anti-ADA antibody (anti-
ADA-FITC, 75 mg/ml) and the rhodamine-
conjugated anti-A1R antibody (PC21-
TRITC, 75 mg/ml). Cells were analyzed
by double immunofluorescence with a
confocal microscope to detect ADA (green
images) and A1R (red images). Superim-
position of images reveals ADA/A1R co-
localization in yellow. Scale bar, 10 mm.
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lized cells. After pretreatment with medium (control) or 50 nM
R-PIA, cells were fixed, and ecto-ADA was labeled using the
anti-ADA-FITC antibody. A significant time-dependent de-
crease in fluorescence intensity was observed after 8 h of R-PIA
treatment, and a maximum decrease (40%) was obtained at
24 h, which suggests A1R agonist-induced internalization of
ecto-ADA (Fig. 7).
To follow ADA internalization, DDT1MF-2 cells were labeled
with ADA-FITC, which binds to cell surface A1Rs (34). The
labeling was performed in the presence or in the absence of 50
nM R-PIA. After extensive washes in acid buffer, cells fixed in
paraformaldehyde were analyzed by flow cytometry. The acidic
wash was necessary to remove ADA-FITC remaining on the cell
surface; therefore, quantification of intracellular fluorescence
is a direct measure of internalized ADA (see “Experimental
Procedures”). A progressive time-dependent incorporation of
fluorescence into the cells, in the period 2–48 h, was observed
in the absence of R-PIA. Maximal incorporation of ADA-FITC,
which occurred at 48 h, increased (37%) in the presence of
R-PIA. The differences between control and R-PIA-treated cells
were significant between 8 and 48 h. Internalization of ADA-
FITC into the cells was also analyzed by immunofluorescence
and confocal assays. Cells maintained in the presence of ADA-
FITC for 24–72 h showed accumulations of labeling in intra-
cellular vesicles. R-PIA treatment for 24–72 h resulted in a
marked increase in intracellular labeling in brighter and larger
intracellular vesicles (Fig. 8A). These variations were not due
to fluid phase internalization, since R-PIA did not affect the
extent of fluorescein-conjugated bovine serum albumin inter-
nalization (Fig. 8B).
As shown in Figs. 5 and 9A and as described elsewhere (32),
R-PIA induces the disappearance of cell surface A1Rs even in
the absence of exogenous ADA. Since cell surface ADA and A1R
colocalize, these results indicate that R-PIA might induce in-
ternalization of A1R together with ADA. We tested this hypoth-
esis by comparing the distribution of A1Rs and ADA in double
immunofluorescence staining experiments analyzed by confo-
cal microscopy. Double immunofluorescence staining with the
FIG. 4. Agonist-induced functional desensitization of A1R in
the absence or presence of ADA. A, cells were loaded with Fura-
2/AM (30 min, 25 °C), resuspended in serum-free DMEM, and preincu-
bated with vehicle (control), 65 nM ADA, 50 nM R-PIA, or 65 nM ADA
plus 50 nM R-PIA for 5 min at 37 °C. After extensive washing, intracel-
lular calcium mobilization was achieved by 50 nM R-PIA as described
under “Experimental Procedures.” Traces correspond to a representa-
tive experiment. Panel B, time course of functional desensitization,
measured as R-PIA-induced intracellular calcium mobilization, after
pretreatment of cells with ADA and/or R-PIA. Intracellular calcium
mobilization was achieved as described in A. For long term desensiti-
zation (12, 24, and 48 h), cells were grown in the presence of the
reagents prior to the loading with Fura-2/AM (see “Experimental Pro-
cedures”). Data are presented as percentage of the maximal response
obtained for control cells stimulated with 50 nM R-PIA. Data are ex-
pressed as mean 6 S.E. of three separate experiments. *, p , 0.05; **,
p , 0.01; ***, p , 0.005 with respect to the untreated cells.
FIG. 5. Loss of cell surface [3H]R-PIA binding sites in response
to ADA and/or R-PIA treatment. Cells were incubated with vehicle
(control), 65 nM ADA (M), 50 nM R-PIA (E), or 65 nM ADA plus 50 nM
R-PIA (l) for the indicated time at 37 °C. After pretreatment, cells were
washed and incubated for 4 h at 4 °C with 5 nM [3H]R-PIA. Nonspecific
binding was assessed in the presence of a 400-fold excess of unlabeled
R-PIA. Data (mean 6 S.E. of five experiments performed in quadrupli-
cate) are presented as percentages of the specific binding with respect to
untreated cells. *, p , 0.005; **, p , 0.001.
FIG. 6. Internalization of A1Rs in cells preincubated with ADA.
DDT1MF-2 cells were treated with 65 nM ADA for 2 h at 4 °C. After
binding of ADA to the cell surface, unbound enzyme was washed away,
and cells were treated without (open bar) or with (striped bar) 50 nM
R-PIA for 24 h at 37 °C. A sample of R-PIA-treated cells was washed
twice in PBS and further cultured for 24 h in absence of the compound
(solid bar). After treatment, cells were harvested, rinsed in PBS, fixed
using 4% paraformaldehyde in PBS, and prepared for immunostaining
using the fluorescein-conjugated anti-A1R antibody (PC21-FITC, 75
mg/ml). Fluorescence quantification was performed on a EPICS Profile
flow cytometer as indicated under “Experimental Procedures.” Data are
presented as percentages with respect to untreated cells. Values repre-
sent the mean 6 S.E. from three separate experiments. *, p , 0.05.
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rhodamine-conjugated rabbit anti-A1R (PC21-TRITC) and flu-
orescein-conjugated ADA (ADA-FITC) was performed in con-
trol and R-PIA-treated cells. Incubation of cells with ADA-
FITC and PC21-TRITC for 24 h showed staining for ADA and
A1R in intracellular vesicles (Fig. 9B, top). Superimposition of
images revealed a high degree of colocalization between the two
proteins (Fig. 9B, yellow). After 24 h of chronic exposure to 50
nM R-PIA, perinuclear staining and a marked decrease in the
number of intracellular vesicles containing ADA and A1Rs,
accompanied by a drastic increase in size and brightness, were
observed (Fig. 9B, bottom). Colocalization of both proteins (yel-
low) was confirmed in numerous cells analyzed at various
planes, indicating that A1Rs and ADA internalize together via
the same pathway of endocytosis.
DISCUSSION
This study provides new insights into ligand-mediated mech-
anisms involved in the regulation and trafficking of A1 adeno-
sine receptors. Several studies have demonstrated agonist de-
sensitization by means of a reduced inhibition of adenylate
cyclase associated with a net loss of binding sites and Gi pro-
teins (29, 30, 31). However, little was known about the bio-
chemical mechanisms involved in desensitization and down-
regulation or the intracellular pathways involved in the
trafficking of A1Rs. Another interesting question concerns the
role of ecto-ADA in the desensitization of A1R due to the fact
that A1R and ADA interact on the cell surface (34). The high
expression (100,000 receptors/cell) of A1Rs (43), capable of in-
teracting with ADA (34) makes DDT1MF-2 cells a suitable
model to study the role of ADA in the regulation of A1R
expression.
By means of immunofluorescence staining using antibodies
against A1R and ADA, a nearly homogenous distribution of A1R
and ADA over the plasma membrane of DDT1MF-2 cells was
observed. Confocal analysis demonstrated a high degree of
colocalization between ADA and A1R, which was maintained in
the cell surface clusters formed after R-PIA treatment. The
appearance of clusters was accelerated when cells were incu-
bated simultaneously with R-PIA and ADA. This suggests an
ADA-mediated regulation of ligand-induced redistribution of
A1Rs. Prolonged agonist stimulation induced the disappear-
ance of membrane A1R binding sites on DDT1MF-2 cell surface,
as previously shown (29). This phenomenon was also acceler-
ated in the presence of ADA, although the maximum effect was
the same as that achieved by R-PIA alone.
Ecto-ADA also underwent R-PIA-induced internalization.
Internalized ADA appeared in relatively small intracellular
vesicles, where it colocalized with A1R. This may be an agonist-
independent process representing the natural recycling of the
ectoenzyme, or it may be due to the presence of endogenous
adenosine. This latter possibility seems unlikely, since no in-
ternalization of A1R occurred in the absence of R-PIA. Al-
though ADA internalization may be agonist-independent, long
term agonist treatment increased the degree of ADA internal-
ization. Double immunofluorescence assays analyzed by confo-
cal microscopy showed colocalization of ADA and A1Rs in the
same intracellular vesicles. All these findings suggest that
ADA and A1Rs participate in the regulation of each other and
that this mutual regulation includes internalization via the
same endocytic pathway. To our knowledge, this is the first
report describing the trafficking of a purine ectoenzyme and
demonstrating a common internalization pathway for A1R and
the ectoprotein (ecto-ADA) interacting with it.
During the agonist-mediated redistribution (clustering) of
A1Rs on the cell surface, a time-dependent phosphorylation of
A1Rs occurs. Basal A1R phosphorylation increased rapidly be-
tween 5 and 15 min as a consequence of agonist stimulation.
Agonist-induced A1R phosphorylation was accelerated and en-
hanced in the presence of exogenous ADA. Taking into account
these data and the fact that ADA increased ligand-induced A1R
aggregation, the involvement of phosphorylation in the cluster-
ing of A1 receptors is highly probable. In fact, clustering and
internalization of A1Rs were mimicked by activators of protein
FIG. 7. Cell surface expression of ADA (ecto-ADA) in response
to R-PIA. Cells were untreated (control) or treated with 50 nM R-PIA
for 0–48 h at 37 °C. Cells were then washed once in PBS, fixed using 4%
paraformaldehyde in PBS, and prepared for immunostaining with the
fluorescein-conjugated anti-ADA antibody (ADA-FITC, 75 mg/ml) as
indicated under “Experimental Procedures.” Fluorescence intensity
was quantified on an EPICS Profile flow cytometer. Data are presented
as percentages with respect to untreated cells. Values represent the
mean 6 S.E. from three separate experiments performed in triplicate.
*, p , 0.05; **, p , 0.01.
FIG. 8. Internalization of fluorescein-conjugated ADA or bo-
vine serum albumin in the absence or presence of R-PIA. A, cells
growing on glass coverslips in the presence of 65 nM fluorescein-conju-
gated ADA were incubated (37 °C) in the absence (2PIA) or presence
(1PIA) of 50 nM R-PIA for 24 or 72 h. Glass coverslips were washed in
PBS, fixed, mounted, and analyzed by confocal microscopy as described
under “Experimental Procedures.” Panel B, cells were grown in the
presence of 65 nM fluorescein-conjugated bovine serum albumin in the
absence (2PIA) or presence (1PIA) of 50 nM R-PIA for 72 h. Cells were
processed as indicated in A. Images correspond to a middle section of
representative cells. Scale bar, 10 mm.
ADA and A1R Internalization 17615
 at Biblioteca de la U
niversitat de Barcelona on A
pril 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
kinase A and protein kinase C (32), thus showing the need for
Ser/Thr phosphorylation in these events. Simultaneous to li-
gand-induced receptor phosphorylation and aggregation, a de-
crease in ligand-induced second messenger response, i.e. a
functional desensitization, was observed. Functional desensiti-
zation was a rapid time-dependent process that occurred
within minutes but remained for hours. This contrasts with
data found in Chinese hamster ovary cells transfected with the
human A1R. Overexpressed A1Rs were neither phosphorylated
nor desensitized after 10 min of R-PIA treatment. Interest-
ingly, a stably expressed chimeric A1-A3 adenosine receptor, in
which the C-terminal domain of A1R distal to its predicted
palmitoylation site was replaced by the corresponding region of
the A3 subtype, was able to undergo functional desensitization
and agonist-stimulated phosphorylation (44). Differences in
amino acid sequence of the C-terminal domain of A1R and A3R
can account for the distinct desensitization pathways found in
Chinese hamster ovary cells. However, the short term desen-
sitization and phosphorylation reported here for A1R in
DDT1MF-2 cells demonstrate that the cellular environment
near the plasma membrane is important for receptor regula-
tion. The regulation of A1R phosphorylation and desensitiza-
tion by cell surface ADA is an example of the relevance of the
membrane components for receptor regulation. To our knowl-
edge, this is a novel finding, since no other receptor whose
function is modulated by an ectoenzyme has been described.
Rapid ligand-induced desensitization of G protein-coupled
receptors such as b2-ARs (45), angiotensin II receptor (46),
cholecystokinin receptor (47), d-opioid receptor (48), and neu-
rokinin 1 receptor (49) correlates with receptor phosphoryla-
tion and uncoupling from G proteins. Several reports have
provided evidence that receptor desensitization is short term
and does not require endocytosis (45, 50, 51). An exception is
the agonist-induced desensitization of the secretin receptor,
which occurs in the absence of receptor phosphorylation and is
basically induced by receptor internalization (52). b2-AR (22,
23) and neurokinin 1 receptor (49) resensitization seems to be
a consequence of receptor dephosphorylation in endosomes and
their recycling back to the plasma membrane. Our data indi-
cate that although receptor phosphorylation returns to basal
level, desensitization of A1R continued for hours (see Figs. 3
and 4). In a recent study, desensitization of the cholecystokinin
receptor occurred in both rat pancreatic acinar cells and trans-
fected Chinese hamster ovary cells, although receptor dephos-
phorylation was evident only in acinar cells. Moreover, chole-
cystokinin receptor in Chinese hamster ovary cells maintained
its phosphorylation state throughout the time of internaliza-
tion, whereas the acinar cell receptor was dephosphorylated to
its basal state while remaining on the cell surface (47). All of
these data suggest differences in regulation of G protein-cou-
pled receptors, depending on the receptor subtype and the cell
system in which the receptor is expressed.
The results provide new insights into the regulation and
trafficking of A1Rs in response to agonist stimulation. More-
over, it is shown that ecto-ADA, besides its role in regulating
the extracellular concentration of adenosine, modulates all the
regulatory mechanisms involved in desensitization of A1R. It is
remarkable that ADA and A1R colocalize on the cell surface
and in intracellular vesicles after internalization. During the
agonist-dependent internalization process, ADA and A1R fol-
low a common endocytic pathway. This is probably the molec-
ular mechanism underlying the recent discovery of increased
plasma adenosine levels found after caffeine or sulfophenylteo-
phylline consumption (53). Although it does not occur in
DDT1MF-2 cells, there are cell types whose A1Rs internalize in
response to xanthine antagonists.2 The probable internaliza-
tion of ADA and A1R from the cell surface in those antagonist-
treated cells would lead to a decrease in adenosine deamination
and, subsequently, to an increase in the extracellular levels of
the nucleoside. As pointed out by Conlay et al. (53), alteration
of adenosine levels by sudden changes in methylxanthine con-
sumption could affect the physiology of many organ systems
and provoke bronchospasm, alter blood pressure, change car-
diac rhythms, or influence seizure thresholds. Confirmation
that internalization of ecto-ADA is the cause of these alter-
ations would be very valuable from a physiological and thera-
peutic point of view.
2 A. Navarro, C. A. Saura, J. Mallol, E. I. Canela, C. Lluis, and R.
Franco, manuscript in preparation.
FIG. 9. Colocalization of internalized ADA and A1 in the absence or presence of R-PIA. A, DDT1MF-2 cells were grown in DMEM
containing fluorescein-conjugated anti-A1R antibody (PC21-FITC, 10 mg/ml) in the absence (top) or in the presence (bottom) of 50 nM R-PIA for 24 h.
After treatment, cells were fixed, washed, and analyzed by confocal microscopy. Images correspond to a middle section of representative cells. Scale
bar, 10 mm. B, DDT1MF-2 cells were grown in DMEM containing fluorescein-conjugated ADA (65 nM) and rhodamine-conjugated anti-A1R antibody
(PC21-TRITC, 10 mg/ml) in the absence (top) or in the presence (bottom) of 50 nM R-PIA for 24 h. After treatment, cells were fixed, washed, and
analyzed by confocal microscopy to detect ADA (green images) and A1R (red images). Superimposition of images reveals the intracellular
colocalization of ADA and A1R in yellow. Scale bar, 10 mm.
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